Search results for " Mab"
Article
Fusion Proteins Pose Manufacturability Challenges
The titers for fusion proteins are generally lower than those for mAbs due to less efficient translation, notes Chamow.
Non-human glycans—such as N-glycolylneuraminic acid and alpha-galactose—are …
Article
Mechanistic Modeling of Preparative Ion-Exchange Chromatography
Mechanistic modeling for development of an ion-exchange chromatography step to purify mAbs
In this section, the authors provide a step-wise method to build an ion-exchange mechanistic model …
Article
Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
… Fc-γ receptors (29) or for the elimination of immune effector functions when non-immunostimulatory mAbs are developed (30).
Bispecifics with combined target and Fc receptor functiona…
Poster
Purification of monoclonal antibodies using modern chromatography media and membranes
This white paper is a guide to the development of MAb purification platforms and provides an overview of Cytiva’s offering of process chromatography media (resins) and membranes for MAb purification…
Poster
Three-step monoclonal antibody purification processes using modern chromatography media
This application note describes monoclonal antibody (MAb) purification processes using the expanded mAb purification toolbox of Cytiva business, covering modern chromatography media (resins) for sta…
Article
SEC in the Modern Downstream Purification Process
In these types of applications, the payload molecule (usually a cytotoxin) is added in a significant excess compared to the amount of mAb. This stoichiometry is necessary to drive the loading of the c…
Article
The Bullish Outlook for Biosimilars
To grasp the potential impact that mAbs will have on the biosimilar market, there are more than 600 mAbs currently in development for oncology alone (10). Together with the fact that insulin biosimila…
Article
Milestones and Moderate Progress in 2012 Drug Approvals
First gene therapy and plant-based expression vector products approved in 2012.
In terms of product approvals, the past year can be considered reasonably successful. Twelve biopharm…
Article
Address the complexity of protein characterization
Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant clinical success and have been used to provide effective treatment for a range of diseases. Durin…
Article
Downstream Process Developers: What are Your Antibody Processing Challenges?
We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants.
Take this short, anonymous survey to share your insights. We’ll …